Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 6/20 | 0.34 |
| ▸ | MAOB | P27338 | 6/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145158 | 0.83 | GBA1 (0.44) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL29081364 | 0.83 | GBA1 (0.44) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL29081362 | 0.83 | GBA1 (0.44) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL24364128 | 0.83 | GBA1 (0.44) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL19500985 | 0.82 | MEN1 (0.46) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL25645589 | 0.82 | MEN1 (0.46) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL170789 | 0.82 | MEN1 (0.46) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL24365906 | 0.80 | PRCP (0.35) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL29081959 | 0.80 | PRCP (0.35) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL29081961 | 0.80 | PRCP (0.35) | PRCPMEN1KMT2ASMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRCP 444/4885MEN1 142/4885KMT2A 4008/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRCP 444/4885MEN1 142/4885KMT2A 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.